Bayer’s Supplement Sales Leap By A Third On COVID Boost
Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic.
You may also be interested in...
A year on from the start of the COVID-19 outbreak and a global rush for supplements, Bayer has cemented these sales gains with slight growth at its Nutritionals business in Q1.
Likely talking points when three of the biggest global consumer health players report Q1 results include: GSK's separation plan and the influence of a new major investor; Sanofi's program to divest over half of its OTC brands; and Bayer's ability to sustain higher sales of dietary supplements post-COVD-19.
Enjoying a 5% sales rise, Bayer Consumer Health grew faster than the global market last year, with the company keen to repeat the performance in 2021.